Analytical Data
-
Gene name
RGS19
- Application
-
Alternative Names
GAIP; RGSGAIP; GNAI3IP; G-alpha-interacting protein
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P49795
-
Expression Region
Met1~Ala217
-
Molecular Weight
31kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
RGS19, also known as Regulator of G Protein Signaling 19, is a member of the RGS protein family that plays a crucial role in modulating G protein-coupled receptor (GPCR) signaling pathways. As GPCRs are pivotal in various physiological processes and represent a major class of drug targets, understanding the regulatory mechanisms of RGS proteins like RGS19 can provide significant insights for therapeutic applications. Research has shown that RGS19 interacts with various G proteins, specifically Gαi and Gαq, thereby accelerating their GTPase activity and promoting signal termination. Dysregulation of RGS19 has been implicated in several diseases, including cancer and cardiovascular disorders, making it a potential biomarker and therapeutic target. The recombinant expression and purification of RGS19 are essential for elucidating its structure-function relationship and for developing specific inhibitors or modulators that could enhance GPCR signaling where needed. Recent advancements in protein engineering techniques have facilitated the production of high-quality, functional RGS19 recombinant proteins, allowing for more detailed biochemical and biophysical studies. Consequently, ongoing research aims to explore its complex interactions, regulatory mechanisms, and potential as a drug target, underscoring the significance of RGS19 in cellular signaling networks.
